Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis

Samantha K. Kurosky[1], Ashley S. Cha-Silva[1], Jenny Austin[2], Arash Mostaghimi[3], Chesahna Kindred[4,5], Genevieve Gauthier[6], Mojgan Sadrarhami[1], Peter Anderson[2], Benjamin Ungar[7]

1. Pfizer Inc, New York, NY, USA
2. Adelphi Real World, Bollington, UK
3. Brigham and Women's Hospital, Boston, MA, USA
4. Kindred Hair & Skin Center, Columbia, MD, USA
5. Howard University, Washington, DC, USA
6. Pfizer Inc, Kirkland, QC, Canada
7. Mount Sinai, New York, NY, USA

Corresponding author: Samantha K. Kurosky (Samantha.Kurosky@pfizer.com)

SUPPLEMENTARY MATERIAL

Figure S1. Study design



AA, alopecia areata; DSP, disease specific programme.

Figure S2. Current disease severity* by ritlecitinib treatment duration among patients† who had (A) severe or (B) very severe disease immediately prior to ritlecitinib initiation



*Disease severity currently and immediately prior to ritlecitinib initiation were based on physician assessment.

†Patients with a known duration of ritlecitinib treatment.

Figure S3. Treatment goals* among patients receiving ritlecitinib (N=123) (A) and reasons for selecting ritlecitinib* among patients receiving ritlecitinib (n=113) (B)



*Reported for ≥10% of patients.